Aligos Therapeutics, Inc.
ALGS
$7.35
-$0.31-3.99%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 4.71M | 2.19M | 2.65M | 3.17M | 3.27M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 4.71M | 2.19M | 2.65M | 3.17M | 3.27M |
| Cost of Revenue | 55.62M | 55.49M | 54.49M | 47.32M | 54.45M |
| Gross Profit | -50.91M | -53.31M | -51.84M | -44.15M | -51.18M |
| SG&A Expenses | 22.07M | 20.72M | 20.93M | 20.40M | 21.22M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 100.38M | 90.17M | 89.38M | 81.68M | 89.62M |
| Operating Income | -95.67M | -87.99M | -86.73M | -78.50M | -86.35M |
| Income Before Tax | -89.73M | -23.88M | -86.15M | -73.84M | -52.91M |
| Income Tax Expenses | 588.00K | 314.00K | 311.00K | 346.00K | 350.00K |
| Earnings from Continuing Operations | -90.32 | -24.19 | -86.46 | -74.18 | -53.26 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -90.32M | -24.19M | -86.46M | -74.18M | -53.26M |
| EBIT | -95.67M | -87.99M | -86.73M | -78.50M | -86.35M |
| EBITDA | -94.59M | -87.06M | -85.82M | -77.56M | -85.41M |
| EPS Basic | -8.70 | -1.36 | -12.53 | -12.56 | -10.21 |
| Normalized Basic EPS | -5.40 | -0.83 | -7.81 | -7.82 | -6.35 |
| EPS Diluted | -8.71 | -8.60 | -19.76 | -19.79 | -17.45 |
| Normalized Diluted EPS | -5.40 | -0.94 | -7.92 | -7.93 | -6.46 |
| Average Basic Shares Outstanding | 41.51M | 39.51M | 35.41M | 31.31M | 27.22M |
| Average Diluted Shares Outstanding | 41.51M | 39.81M | 35.71M | 31.62M | 27.53M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |